Base de datos : MEDLINE
Búsqueda : Fluocortolona [Palabras]
Referencias encontradas : 265 [refinar]
Mostrando: 1 .. 10   en el formato [Detallado]

página 1 de 27 va a la página                         

  1 / 265 MEDLINE  
              next record last record
selecciona
para imprimir
Fotocopia
[PMID]:25007376
[Au] Autor:Del Rosso JQ; Kircik LH
[Ti] Título:Transitioning from brand to generic with topical products and the importance of maintaining the formulation and therapeutic profiles of the original product: focus on clocortolone pivalate 0.1% cream.
[So] Fuente:J Drugs Dermatol;13(7):s77-83, 2014 Jul.
[Is] ISSN:1545-9616
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:Topical corticosteroids (TCSs) are a major part of the foundation of treatment for a wide variety of eczematous and inflammatory skin disorders in both adults and children. Mid-potency TCSs represent an important category as they are often used to treat eczematous dermatoses, such as atopic dermatitis. The TCS product must effectively release the active ingredient and promote cutaneous penetration so that therapeutic activity can occur. As many topical products eventually become available as generic formulations, it is important to recognize that although the active ingredient and its concentration are the same, the vehicle excipients may differ significantly, occasionally leading to potential differences in irritancy, in allergenicity, in effects on epidermal permeability barrier function, and, possibly, in efficacy. Clocortolone pivalate 0.1% cream is a mid-potency TCS formulated in an emollient formulation that has been shown to be effective and well-tolerated in the management of several corticosteroid-responsive dermatoses. This article outlines the pharmacologic and clinical data achieved with the original brand formulation of clocortolone pivalate 0.1% cream, and discusses the establishment of an authorized generic formulation that is identical in formulation to the original brand.
[Mh] Términos MeSH primario: Medicamentos Genéricos/administración & dosificación
Fluocortolona/análogos & derivados
Glucocorticoides/administración & dosificación
[Mh] Términos MeSH secundario: Administración Cutánea
Adulto
Niño
Fármacos Dermatológicos/administración & dosificación
Fármacos Dermatológicos/efectos adversos
Fármacos Dermatológicos/uso terapéutico
Medicamentos Genéricos/efectos adversos
Medicamentos Genéricos/uso terapéutico
Eccema/tratamiento farmacológico
Eccema/patología
Excipientes/química
Fluocortolona/administración & dosificación
Fluocortolona/efectos adversos
Fluocortolona/uso terapéutico
Glucocorticoides/efectos adversos
Glucocorticoides/uso terapéutico
Seres Humanos
Inflamación/tratamiento farmacológico
Inflamación/patología
Enfermedades de la Piel/tratamiento farmacológico
Enfermedades de la Piel/patología
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Nm] Nombre de substancia:
0 (Dermatologic Agents); 0 (Drugs, Generic); 0 (Excipients); 0 (Glucocorticoids); 65VXC1MH0J (Fluocortolone); QBL8IZH14X (clocortolone pivalate)
[Em] Mes de ingreso:1503
[Cu] Fecha actualización por clase:151119
[Lr] Fecha última revisión:151119
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:140710
[St] Status:MEDLINE


  2 / 265 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
[PMID]:24809882
[Au] Autor:Kircik LH
[Ti] Título:A study to assess the occlusivity and moisturization potential of three topical corticosteroid products using the skin trauma after razor shaving (STARS) bioassay.
[So] Fuente:J Drugs Dermatol;13(5):582-5, 2014 May.
[Is] ISSN:1545-9616
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:Dysfunction of the epidermal barrier is generally considered a precursor of cutaneous inflammation that can directly contribute to the pathogenesis of skin diseases, notably atopic dermatitis (AD). We also know that topical corticosteroids may actually impair the epidermal barrier by interfering with epidermal lipid synthesis. Therefore, it is important to utilize topical corticosteroids in vehicles that will help at least to enhance the already disrupted epidermal barrier in atopic dermatitis patients. Two studies of identical design were conducted to determine and compare the occlusivity and moisturizing potential of three topical corticosteroid products when applied to skin whose barrier integrity has been disrupted by dry shaving. Findings in both studies showed the clocortolone pivalate cream decreased TEWL better than non-treatment or treatment with hydrocortisone butyrate lotion. Skin surface hydration increased significantly (P<0.001) in all three treated sites, compared to the non-treated damaged control and non-treated normal skin. Clocortolone pivalate cream increased skin surface hydration significantly (P<0.001) better than hydrocortisone butyrate lipocream or hydrocortisone butyrate lotion. These studies showed that clocortolone pivalate cream enhances barrier function by providing occlusion. While understanding of the structure and function of the stratum corneum (SC) and epidermal barrier function has evolved tremendously over the last several decades, and especially over the last 15 years,1 confusion and misinformation still persist. Dysfunction of the epidermal barrier is generally considered a precursor of cutaneous inflammation that can directly contribute to the pathogenesis of skin diseases, notably atopic dermatitis (AD).2,3 Topical steroids are standard of care in treatment of atopic dermatitis. However, we also know that topical corticosteroids may actually impair epidermal barrier by interfering with epidermal lipid synthesis.4,5 In addition to that, various penetration enhancers in the topical steroid formulations also contribute to the impairment of the epidermal barrier.4 Therefore, it is important to utilize topical corticosteroids in vehicles that will help at least to enhance the already disrupted epidermal barrier in atopic dermatitis patients. In this regard, these studies were designed to determine the hydrating effects of clocortolone pivalate cream 0.1% (Cloderm Cream, Promius Pharma).
[Mh] Términos MeSH primario: Fármacos Dermatológicos/farmacología
Fluocortolona/análogos & derivados
Glucocorticoides/farmacología
Hidrocortisona/análogos & derivados
[Mh] Términos MeSH secundario: Administración Cutánea
Adulto
Bioensayo
Dermatitis Atópica/tratamiento farmacológico
Dermatitis Atópica/patología
Fármacos Dermatológicos/administración & dosificación
Emolientes/administración & dosificación
Emolientes/farmacología
Epidermis/efectos de los fármacos
Epidermis/patología
Fluocortolona/administración & dosificación
Fluocortolona/farmacología
Glucocorticoides/administración & dosificación
Seres Humanos
Hidrocortisona/administración & dosificación
Hidrocortisona/farmacología
Mediana Edad
Piel/efectos de los fármacos
Piel/patología
Enfermedades de la Piel/tratamiento farmacológico
Enfermedades de la Piel/patología
Resultado del Tratamiento
Pérdida Insensible de Agua/efectos de los fármacos
Adulto Joven
[Pt] Tipo de publicación:COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nombre de substancia:
0 (Dermatologic Agents); 0 (Emollients); 0 (Glucocorticoids); 05RMF7YPWN (hydrocortisone-17-butyrate); 65VXC1MH0J (Fluocortolone); QBL8IZH14X (clocortolone pivalate); WI4X0X7BPJ (Hydrocortisone)
[Em] Mes de ingreso:1412
[Cu] Fecha actualización por clase:151119
[Lr] Fecha última revisión:151119
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:140510
[St] Status:MEDLINE


  3 / 265 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:24225379
[Au] Autor:Prokosch V; Thanos S
[Ad] Dirección:Institute of Experimental Ophthalmology, Westfälische Wilhelms-Universität Münster, Münster, Germany.
[Ti] Título:Visual outcome of patients following NAION after treatment with adjunctive fluocortolone.
[So] Fuente:Restor Neurol Neurosci;32(3):381-9, 2014.
[Is] ISSN:1878-3627
[Cp] País de publicación:Netherlands
[La] Idioma:eng
[Ab] Resumen:PURPOSE: Nonarteriitic anterior ischemic optic neuropathy (NAION) is a leading cause of sudden loss of vision, which particularly affects individuals older than 50 years. Up to now there is no treatment that is effective at reversing or limiting the course of this disease. To study the short- and long-term effects of fluocortolone (FC) on the visual outcome of patients with acute NAION compared to standard treatment with pentoxifylline (PFX). METHODS: A prospective, quasirandomized intervention trial was conducted involving 60 patients with acute-onset NAION. Patients in the comparison (PFX) group (n = 30) received PFX intravenously and per os for 7 days and then per os for a further 6 months, which is a standard treatment. Patients in the intervention (PFX + FC) group (n = 30) received the standard treatment plus 1 mg/kg FC for 5 days, with a subsequent stepwise dose reduction over time. As a primary outcome measure, the best corrected visual acuity (BCVA) was determined at the initial baseline consultation (i.e., before treatment), and at 3 days and 6 months after therapy onset. Visual field (VF) was analyzed using standard automated perimetry at the initial baseline examination and at 6 month after therapy onset. Changes in BCVA and visual field in the PFX and PFX + FC groups were compared and analyzed statistically. RESULTS: Treatment with FC resulted in a significant improvement in BCVA. Patients receiving FC in acute NAION were more likely to experience improvement and less likely to have worsened visual acuity (mean BCVA scores: at baseline, 0.22; after 3 days and 6 months of treatment, 0.33 and 0.43, respectively) than PFX patients (mean BCVA scores: at baseline, 0.33; after 3 days and 6 months of treatment, 0.33 and 0.28, respectively; p < 0.002 and 0.001). The beneficial effect was even more marked 6 months after therapy onset. Remarkably, patients with a baseline BCVA score of >=0.05 profited significantly by FC treatment (p < 0.006 and 0.001), whereas those with a baseline BCVA score of <0.05 did not (p < 0.4). PFX did not improve BCVA. However, VF did not show any significant improvement due to FC therapy. CONCLUSION: This is the first prospective randomized intervention trial that demonstrates the distinctive beneficial effects of FC in terms of the visual outcome of patients with NAION compared to standard treatment with only PFX. FC significantly improves both short- and long-term visual acuity in patients with moderate BCVA impairment due to recent onset of NAION, while VF did not show any significant improvement; however, PFX did neither enhance BCVA nor VF. Administration of FC should be seriously considered for the treatment of NAION whenever there are no contraindications.
[Mh] Términos MeSH primario: Fluocortolona/uso terapéutico
Fármacos Neuroprotectores/uso terapéutico
Neuropatía Óptica Isquémica/tratamiento farmacológico
Pentoxifilina/uso terapéutico
[Mh] Términos MeSH secundario: Adulto
Anciano
Anciano de 80 o más Años
Femenino
Seres Humanos
Masculino
Mediana Edad
Estudios Prospectivos
Factores de Tiempo
Resultado del Tratamiento
Pruebas de Visión
Agudeza Visual/efectos de los fármacos
[Pt] Tipo de publicación:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nombre de substancia:
0 (Neuroprotective Agents); 65VXC1MH0J (Fluocortolone); SD6QCT3TSU (Pentoxifylline)
[Em] Mes de ingreso:1501
[Cu] Fecha actualización por clase:140603
[Lr] Fecha última revisión:140603
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:131115
[St] Status:MEDLINE
[do] DOI:10.3233/RNN-120292


  4 / 265 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
[PMID]:23377405
[Au] Autor:Del Rosso JQ; Kircik LH
[Ad] Dirección:Valley Hospital Medical Center, Las Vegas, NV, USA.
[Ti] Título:The role of a midpotency topical corticosteroid and the clinical relevance of formulation characteristics in the management of commonly encountered eczematous and inflammatory dermatoses in adults and children: focus on the pharmacologic properties of clocortolone pivalate 0.1% cream.
[So] Fuente:J Drugs Dermatol;12(2):s5-s10, 2013 Feb.
[Is] ISSN:1545-9616
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:Midpotency topical corticosteroids (TCSs) are frequently used for the treatment of common eczematous and inflammatory skin disorders in both adults and children. There are several commercially available products in this category, and many vehicles and formulations for the clinician to choose from. Clocortolone pivalate 0.1% cream is a midpotency TCS formulated in an emollient formulation that has been shown to be effective and well tolerated when used appropriately in the management of several corticosteroid-responsive dermatoses. This article discusses the physiochemical properties of the compound; the characteristics of its emollient cream formulation; the functions of individual excipients; and the efficacy, tolerability, and safety data supporting its use in adults and children, including for facial involvement.
[Mh] Términos MeSH primario: Eccema/tratamiento farmacológico
Fluocortolona/análogos & derivados
Glucocorticoides/uso terapéutico
Enfermedades de la Piel/tratamiento farmacológico
[Mh] Términos MeSH secundario: Administración Tópica
Adulto
Química Farmacéutica
Niño
Dermatitis por Contacto/tratamiento farmacológico
Dermatitis por Contacto/patología
Eccema/patología
Cara
Fluocortolona/administración & dosificación
Fluocortolona/efectos adversos
Fluocortolona/uso terapéutico
Glucocorticoides/administración & dosificación
Glucocorticoides/efectos adversos
Seres Humanos
Pomadas
Psoriasis/tratamiento farmacológico
Psoriasis/patología
Piel/patología
Enfermedades de la Piel/patología
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Nm] Nombre de substancia:
0 (Glucocorticoids); 0 (Ointments); 65VXC1MH0J (Fluocortolone); QBL8IZH14X (clocortolone pivalate)
[Em] Mes de ingreso:1308
[Cu] Fecha actualización por clase:151119
[Lr] Fecha última revisión:151119
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:130205
[St] Status:MEDLINE


  5 / 265 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
[PMID]:23377404
[Au] Autor:Kircik LH
[Ad] Dirección:Mount Sinai Medical Center, New York, NY, USA. wedoderm@yahoo.com
[Ti] Título:Clocortolone pivalate: a topical corticosteroid with a unique structure.
[So] Fuente:J Drugs Dermatol;12(2):s3-4, 2013 Feb.
[Is] ISSN:1545-9616
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:As the accumulated clinical evidence and experience to be presented in the next several pages demonstrate, the unique engineering of the clocortolone pivalate molecule balances potency with documented efficacy and a favorable safety profile. Clocortolone pivalate 0.1% cream is a well-formulated and versatile therapeutic option to consider for many of our patients with steroid-responsive dermatoses.
[Mh] Términos MeSH primario: Fluocortolona/análogos & derivados
Glucocorticoides/química
Glucocorticoides/uso terapéutico
[Mh] Términos MeSH secundario: Administración Tópica
Ensayos Clínicos Fase III como Asunto
Dermatitis/tratamiento farmacológico
Emolientes
Fluocortolona/química
Fluocortolona/uso terapéutico
Halógenos/química
Seres Humanos
Psoriasis/tratamiento farmacológico
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Nm] Nombre de substancia:
0 (Emollients); 0 (Glucocorticoids); 0 (Halogens); 65VXC1MH0J (Fluocortolone); QBL8IZH14X (clocortolone pivalate)
[Em] Mes de ingreso:1308
[Cu] Fecha actualización por clase:151119
[Lr] Fecha última revisión:151119
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:130205
[St] Status:MEDLINE


  6 / 265 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:22573413
[Au] Autor:Birnbaum F; Wiggermann A; Maier PC; Böhringer D; Reinhard T
[Ad] Dirección:Eye Hospital, Klinikum Bremen-Mitte gGmbH, St.-Jürgenstr. 1, 28177 Bremen, Germany. florian.birnbaum@klinikum-bremen-mitte.de
[Ti] Título:Clinical results of 123 femtosecond laser-assisted penetrating keratoplasties.
[So] Fuente:Graefes Arch Clin Exp Ophthalmol;251(1):95-103, 2013 Jan.
[Is] ISSN:1435-702X
[Cp] País de publicación:Germany
[La] Idioma:eng
[Ab] Resumen:BACKGROUND: Postoperative astigmatism following penetrating keratoplasty is a major problem after corneal transplantation. The main goal of new trephination techniques such as femtosecond laser or excimer-laser trephination is to improve refractive and visual outcomes. The femtosecond laser technique makes profiled corneal trephinations such as the top hat or mushroom profile possible. We present the postoperative outcome of femtosecond laser-assisted penetrating keratoplasties. METHODS: We performed 123 femtosecond laser-assisted penetrating keratoplasties in 119 patients. The main outcome measures were intraoperative specifics, astigmatism, and irregularity in Orbscan corneal topography, as well as the occurrence of immune reactions and side-effects. RESULTS: All sutures have been removed in 49 of these 123 eyes. Their mean follow-up was 13.9 ± 4.5 months. Time to complete suture removal (n = 49) was 12.0 ± 3.7 months in the mushroom group and 9.8 ± 2.1 months in the top hat group. Mean astigmatism in Orbscan topography was 6.4 ± 3.0 diopters in the mushroom and 5.8 ± 4.6 diopters in the top hat group (all sutures out). CONCLUSIONS: Femtosecond laser-assisted penetrating keratoplasty is a safe surgical technique. Due to the steps in profiled trephinations, the wound area is larger and theoretically the wound healing is, thus, faster and more stable. Complete suture removal is possible at an earlier time point compared to conventional penetrating keratoplasty. However, refractive results are not superior to those following conventional trephination.
[Mh] Términos MeSH primario: Astigmatismo/etiología
Queratoplastia Penetrante/métodos
Terapia por Láser/métodos
Complicaciones Posoperatorias
[Mh] Términos MeSH secundario: Adulto
Astigmatismo/diagnóstico
Astigmatismo/fisiopatología
Enfermedades de la Córnea/inmunología
Enfermedades de la Córnea/fisiopatología
Enfermedades de la Córnea/cirugía
Topografía de la Córnea
Femenino
Fluocortolona/uso terapéutico
Glucocorticoides/uso terapéutico
Rechazo de Injerto/tratamiento farmacológico
Rechazo de Injerto/inmunología
Seres Humanos
Masculino
Mediana Edad
Prednisolona/análogos & derivados
Prednisolona/uso terapéutico
Refracción Ocular/fisiología
Técnicas de Sutura
Tomografía de Coherencia Óptica
Resultado del Tratamiento
Agudeza Visual/fisiología
Cicatrización de Heridas/fisiología
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Nm] Nombre de substancia:
0 (Glucocorticoids); 65VXC1MH0J (Fluocortolone); 8B2807733D (prednisolone acetate); 9PHQ9Y1OLM (Prednisolone)
[Em] Mes de ingreso:1306
[Cu] Fecha actualización por clase:170928
[Lr] Fecha última revisión:170928
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:120511
[St] Status:MEDLINE
[do] DOI:10.1007/s00417-012-2054-0


  7 / 265 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
[PMID]:23134984
[Au] Autor:Kircik LH; Del Rosso JQ
[Ad] Dirección:Indiana University School of Medicine, Indianapolis, IN, USA. wedoderm@yahoo.com
[Ti] Título:The treatment of inflammatory facial dermatoses with topical corticosteroids: focus on clocortolone pivalate 0.1% cream.
[So] Fuente:J Drugs Dermatol;11(10):1194-8, 2012 Oct.
[Is] ISSN:1545-9616
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:OBJECTIVE: Study results evaluating the efficacy and safety of clocortolone pivalate 0.1% cream in the treatment of adults, young children, and infants with inflammatory facial dermatoses are reported in this article. Clocortolone pivalate 0.1% cream, indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, is a mid-potency topical corticosteroid (Class 4) that has been studied and used extensively to treat a variety of corticosteroid-responsive inflammatory dermatoses, many of which often involve facial skin in both adults and children. METHODS: Clocortolone pivalate 0.01% cream was applied to affected facial skin in subjects presenting with seborrheic dermatitis, contact dermatitis, atopic dermatitis, or psoriasis. Application was completed three times daily for 21 days. Assessments of erythema, edema, transudation, lichenification, scaling, pruritus and/or pain were completed at baseline and Days 4, 7, 14, and 21. Overall therapeutic response was assessed at all follow-up visits. Forty-nine subjects were entered, ranging in age from 1 month to 88 years of age. Thirty-eight subjects completed the studies, with 11 subjects lost to follow-up after the first visit. Individuals between the ages of 13 and 19 years were pre-emptively excluded to avoid potential application of a corticosteroid to acne-affected or acne-prone skin. RESULTS: Treatment with clocortolone pivalate 0.1% cream resulted in decreases in erythema, edema, transudation, lichenification, scaling, and pruritus/pain in 76% of treated study subjects. The overall therapeutic response in approximately two-thirds of the subjects (68%) was rated as good to excellent. There were 7 adverse events noted over the course of the study that were judged to be related to treatment, all of which were cutaneous and localized to the site of application (acneiform eruptions, burning, and folliculitis). CONCLUSION: Clocortolone pivalate 0.1% cream was effective in relieving the signs and symptoms of corticosteroid-responsive inflammatory dermatoses involving facial skin, including seborrheic dermatitis, contact dermatitis, atopic dermatitis, and psoriasis. Overall, the safety profile was favorable and devoid of any treatment-related serious adverse events.
[Mh] Términos MeSH primario: Dermatosis Facial/tratamiento farmacológico
Fluocortolona/análogos & derivados
Glucocorticoides/uso terapéutico
[Mh] Términos MeSH secundario: Adulto
Anciano
Anciano de 80 o más Años
Niño
Preescolar
Dermatitis Atópica/complicaciones
Dermatitis Atópica/tratamiento farmacológico
Dermatitis por Contacto/complicaciones
Dermatitis por Contacto/tratamiento farmacológico
Dermatitis Seborreica/complicaciones
Dermatitis Seborreica/tratamiento farmacológico
Edema/tratamiento farmacológico
Edema/etiología
Eritema/tratamiento farmacológico
Eritema/etiología
Exudados y Transudados/efectos de los fármacos
Dermatosis Facial/complicaciones
Femenino
Fluocortolona/efectos adversos
Fluocortolona/uso terapéutico
Glucocorticoides/efectos adversos
Seres Humanos
Lactante
Masculino
Mediana Edad
Dolor/tratamiento farmacológico
Dolor/etiología
Prurito/tratamiento farmacológico
Prurito/etiología
Psoriasis/complicaciones
Psoriasis/tratamiento farmacológico
Crema para la Piel
Resultado del Tratamiento
Adulto Joven
[Pt] Tipo de publicación:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nombre de substancia:
0 (Glucocorticoids); 65VXC1MH0J (Fluocortolone); QBL8IZH14X (clocortolone pivalate)
[Em] Mes de ingreso:1305
[Cu] Fecha actualización por clase:151119
[Lr] Fecha última revisión:151119
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:121109
[St] Status:MEDLINE


  8 / 265 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
[PMID]:22505393
[Au] Autor:Deniz K; Coban G; Ozbakir O; Deniz E
[Ti] Título:Pseudomembranous collagenous colitis.
[So] Fuente:Turk J Gastroenterol;23(1):93-5, 2012 Feb.
[Is] ISSN:2148-5607
[Cp] País de publicación:Turkey
[La] Idioma:eng
[Mh] Términos MeSH primario: Colitis Colagenosa/diagnóstico
Enterocolitis Seudomembranosa/diagnóstico
[Mh] Términos MeSH secundario: Antiinflamatorios no Esteroideos/uso terapéutico
Colitis Colagenosa/tratamiento farmacológico
Colonoscopía
Diarrea/etiología
Enterocolitis Seudomembranosa/tratamiento farmacológico
Fluocortolona/uso terapéutico
Hemorragia Gastrointestinal/etiología
Glucocorticoides/uso terapéutico
Seres Humanos
Masculino
Mesalamina/uso terapéutico
Mediana Edad
[Pt] Tipo de publicación:CASE REPORTS; LETTER
[Nm] Nombre de substancia:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Glucocorticoids); 4Q81I59GXC (Mesalamine); 65VXC1MH0J (Fluocortolone)
[Em] Mes de ingreso:1209
[Cu] Fecha actualización por clase:150518
[Lr] Fecha última revisión:150518
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:120417
[St] Status:MEDLINE


  9 / 265 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:22264563
[Au] Autor:Xu W; Jia X; Liu W; Zhang X; Chen Y; Zhou L; You S
[Ad] Dirección:School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, People's Republic of China.
[Ti] Título:Identification and characterization of three impurities in clocortolone pivalate.
[So] Fuente:J Pharm Biomed Anal;62:167-71, 2012 Mar 25.
[Is] ISSN:1873-264X
[Cp] País de publicación:England
[La] Idioma:eng
[Ab] Resumen:Clocortolone pivalate is a synthetic corticosteroid that can be used to cure corticosteroid-responsive dermatoses. Three previously unknown impurities detected by HPLC were isolated by semi-preparative LC. Based on the NMR and MS spectral data, these were identified as (6R,9R,16R)-9-chloro-6ß-fluoro-11ß,21-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione-21-pivalate (Impurity I), (9R,16R)-9-chloro-4-fluoro-11ß,21-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione-21-pivalate (Impurity II) and (9R,16R)-9-chloro-6α-fluoro-11ß,21-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione-11,21-dipivalate (Impurity III). The possible mechanism of the formation of the impurities is discussed.
[Mh] Términos MeSH primario: Fluocortolona/análogos & derivados
Glucocorticoides/química
[Mh] Términos MeSH secundario: Cromatografía Líquida de Alta Presión
Fluocortolona/química
Espectroscopía de Resonancia Magnética
Espectrometría de Masa por Ionización de Electrospray
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nombre de substancia:
0 (Glucocorticoids); 65VXC1MH0J (Fluocortolone); QBL8IZH14X (clocortolone pivalate)
[Em] Mes de ingreso:1206
[Cu] Fecha actualización por clase:151119
[Lr] Fecha última revisión:151119
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:120124
[St] Status:MEDLINE
[do] DOI:10.1016/j.jpba.2011.11.021


  10 / 265 MEDLINE  
              first record previous record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:21437845
[Au] Autor:Mayer C; Khoramnia R
[Ad] Dirección:Klinik und Poliklinik für Augenheilkunde, Klinikum rechts der Isar der Technischen Universität München, München. christian.mayer@lrz.tu-muenchen.de
[Ti] Título:[Choroidal neovascularisation in a patient with punctate inner choroidopathy (PIC)].
[Ti] Título:Choroidale Neovaskularisation bei einer Patientin mit "punctate inner choroidopathy" (PIC)..
[So] Fuente:Klin Monbl Augenheilkd;228(10):915-7, 2011 Oct.
[Is] ISSN:1439-3999
[Cp] País de publicación:Germany
[La] Idioma:ger
[Mh] Términos MeSH primario: Enfermedades de la Coroides/diagnóstico
Neovascularización Coroidal/diagnóstico
[Mh] Términos MeSH secundario: Adulto
Antiinflamatorios/administración & dosificación
Anticuerpos Monoclonales Humanizados/administración & dosificación
Bevacizumab
Enfermedades de la Coroides/tratamiento farmacológico
Neovascularización Coroidal/tratamiento farmacológico
Progresión de la Enfermedad
Femenino
Fluocortolona/administración & dosificación
Angiografía con Fluoresceína
Estudios de Seguimiento
Seres Humanos
Procesamiento de Imagen Asistida por Computador
Oftalmoscopios
Tomografía de Coherencia Óptica
Trastornos de la Visión/diagnóstico
Trastornos de la Visión/tratamiento farmacológico
Trastornos de la Visión/etiología
[Pt] Tipo de publicación:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nombre de substancia:
0 (Anti-Inflammatory Agents); 0 (Antibodies, Monoclonal, Humanized); 2S9ZZM9Q9V (Bevacizumab); 65VXC1MH0J (Fluocortolone)
[Em] Mes de ingreso:1204
[Cu] Fecha actualización por clase:151119
[Lr] Fecha última revisión:151119
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:110326
[St] Status:MEDLINE
[do] DOI:10.1055/s-0029-1245792



página 1 de 27 va a la página                         
   


Refinar la búsqueda
  Base de datos : MEDLINE Formulario avanzado   

    Buscar en el campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPS/OMS - Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud